NCT02590263 (Clinical Trial/ ABT-414)

Study Title

Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma (NCT02590263)

Trial Description

This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.

This trial is sponsored by AbbVie.®

Study Data

  • Condition:
    • Malignant Glioma
    • Glioblastoma
  • Interventions:
    • Drugs used in this trial
      • ABT-414
      • Temozolomide
      • Radiation: Whole Brain Radiation
  • Phase: I
  • Enrollment: 46
  • Start: September 2015
  • Estimated Completion: July 2018
  • Last verified: May 2017
  • Last Updated: May 2017

Study Schematic

(Coming soon)

Click here to Return to Drug map


Last Editorial review: August 28, 2017
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.